Genentech’s combo aims to treat HER2-positive early breast cancer after surgery
News
Child brain cancer treatments can be personalised: study
Currently-incurable tumours can be split into ten different disease
NICE knocks-back Janssen’s Imbruvica in mantle cell lymphoma
But recommends it for the rare cancer Waldenstrom’s macroglobulinaemia
Brexit move creates EMA risk: report
Report says several functions of the Agency, and public health, could be at risk
Sanofi’s Dupixent gets Europe eczema nod
Drug becomes first targeted biologic in Europe to treat moderate-to-severe atopic dermatitis (AD)
Ergomed makes moves to acquire Dutch CRO
Will purchase PSR Group in a deal worth €5.7 million
AHSN develops kidney toolkit for GPs
Aims to improve early recognition of Acute Kidney Injury
FDA lukewarm on PTC’s Translarna
Agency says studies into Duchenne muscular dystrophy drug were inconclusive
EMA staff favour move to Amsterdam
Body warns of ‘public health crisis’ if move results in significant loss of staff
UK CRO Quanticate doubles its footprint in India
Opens new Bangalore office to bolster its global offering
EC approves Janssen’s Symtuza
Drug is only darunavir-based STR indicated for HIV-1 infection in adults and adolescents
Allergan embarks on $2 billion share repurchase
Company believes that its stock is undervalued
Glythera teams with Cancer Research UK
Partnership will focus on antibody drug conjugates
MSD launches once-daily Isentress in the UK
Will be better placed to compete head on with ViiV’s rival integrase inhibitor Tivicay
EU green light for Roche’s Tecentriq
Anti-PD-L1 cancer immunotherapy approved to treat specific lung and bladder cancers
